Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.
Leukemia
View this publicationLeukemia
View this publicationCurrent opinion in microbiology
View this publicationHeart and vessels
View this publicationNaunyn-Schmiedeberg's archives of pharmacology
View this publicationPediatric blood & cancer
View this publicationLancet (London, England)
View this publicationJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
View this publicationJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
View this publicationCell and tissue research
View this publicationCancer discovery
View this publication